Sarilumab: a new IL-6 receptor blocker for rheumatoid arthritis

Sarilumab (Kevzara) is the second monoclonal antibody against the IL-6 receptor to be licensed for the treatment of rheumatoid arthritis. This article examines its indications, efficacy and adverse effects.

Read the full article

Add yours ↓
Web design and marketing agency Leamington Spa